Company news

AtaiBeckley Inc. news in 2026

AtaiBeckley Inc.'s news releases, calls and decks from 2026, newest first.

View company

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

July 6, 2026

AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets

June 25, 2026

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

May 28, 2026

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

May 26, 2026

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

May 12, 2026

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

April 27, 2026

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

April 22, 2026

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

April 14, 2026

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

April 8, 2026

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

March 24, 2026

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

March 17, 2026

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

March 9, 2026

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

March 5, 2026

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

March 2, 2026

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

February 25, 2026

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

February 19, 2026

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

February 18, 2026

AtaiBeckley To Participate in Upcoming Investor Conferences

February 17, 2026

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

January 15, 2026

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

January 7, 2026

Decks in 2026